PCM
TSHA icon

Prelude Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Prelude Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-186,591
Closed -$418K – 1549
2024
Q2 		$418K Buy
186,591
+130,698
+234% +$380K 0.03% 622
2024
Q1 		$160K Sell
55,893
-133,983
-71% -$279K 0.01% 1150
2023
Q4 		$336K Sell
189,876
-50,375
-21% -$100K 0.02% 686
2023
Q3 		$759K Buy
+240,251
New +$449K 0.05% 369

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Prelude Capital Management's TSHA Position: Q3 2024 in Review

Prelude Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 186,591 shares — an estimated $418K sold.

Prelude Capital Management first reported a position in TSHA in Q3 2023 and held it in 4 quarters. The position peaked at $759K in Q3 2023. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Prelude Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 186,591 Taysha Gene Therapies shares in Q3 2024, an estimated $418K.
  • Prelude Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 4 quarters.
  • Prelude Capital Management's Taysha Gene Therapies position peaked at $759K in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.